At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Aug 26, 2026 at 07:30 ET
BridgeBio announced first patient dosed in ASCEND-ATTR, a Phase 3b/4 study of acoramidis in ATTR-CM, designed to assess long-term effects on cardiac structure, function, and amyloid burden. This builds on encouraging CMR substudy data from the Phase 3 ATTRibute-CM trial suggesting potential disease reversal. The study is prospective and open-label, enrolling ~150 patients with annual imaging over 36 months.
- First participant dosed in ASCEND-ATTR, a Phase 3b/4 open-label study of acoramidis in ATTR-CM
- Study will enroll ~150 participants with annual CMR and echocardiography over 36 months
- Primary endpoint: responder status at Month 36 by CMR based on improvement in LV systolic function
- Acoramidis is the only oral, near-complete (≥90%) TTR stabilizer approved (Attruby) for ATTR-CM
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access